Ablation of atrioventricular-nodal-reentrant- tachycardia in a patient with left-sided superior vena cava and dilated coronary sinus

Autor: Deshpande, SA, Udyavar, AR

Publikováno v: Journal of Postgraduate Medicine, Vol 66, Iss 3, Pp 159-161 (2020)
Journal of Postgraduate Medicine

Atrioventricular (AV)-nodal-reentrant-tachycardia is a rare association in a patient with persistent left-sided superior vena cava and dilated coronary sinus. There are a few inherent difficulties in ablation in this condition, viz., difficulty in lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::48f2831c4756160ea69900bc86a9e300
http://www.jpgmonline.com/article.asp?issn=0022-3859

Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.

Autor: Yan W; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Chung CY; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Xie T; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Ozeck M; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Nichols TC; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Frey J; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Udyavar AR; Arcus Biosciences, Hayward, CA, USA., Sharma S; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA., Paul TA; Oncology Research Discovery, Pfizer Worldwide Research and Development, San Diego, CA, USA.

Publikováno v: Molecular oncology [Mol Oncol] 2022 Mar; Vol. 16 (6), pp. 1309-1328. Date of Electronic Publication: 2021 Nov 09.

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.

Autor: Desbois M; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Udyavar AR; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA., Ryner L; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Kozlowski C; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Guan Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Dürrbaum M; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA., Lu S; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Fortin JP; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA., Koeppen H; Department of Research Pathology, Genentech, Inc., South San Francisco, CA, USA., Ziai J; Department of Research Pathology, Genentech, Inc., South San Francisco, CA, USA., Chang CW; Department of Biostatistics, Genentech, Inc., South San Francisco, CA, USA., Keerthivasan S; Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA., Plante M; Laval University Cancer Research Center, Hôtel-Dieu-de-Québec, Centre Hospitalier Universitaire (CHU) de Québec, 11 Côte du Palais, Québec, QC, G1R 2J6, Canada., Bourgon R; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA., Bais C; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Hegde P; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA., Daemen A; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA., Turley S; Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA., Wang Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. wang.yulei@gene.com.

Publikováno v: Nature communications [Nat Commun] 2020 Nov 04; Vol. 11 (1), pp. 5583. Date of Electronic Publication: 2020 Nov 04.

Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies.

Autor: Zheng, Siwei^1,2 (AUTHOR), Wang, Wenwen³ (AUTHOR), Shen, Lesang^1,2 (AUTHOR), Yao, Yao^1,2 (AUTHOR), Xia, Wenjie⁴ (AUTHOR) xiawenjie1031@zju.edu.cn, Ni, Chao^1,2 (AUTHOR) drnichao@zju.edu.cn

Publikováno v: Experimental Hematology & Oncology. 8/6/2024, Vol. 13 Issue 1, p1-33. 33p.

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.

Autor: Wilson TR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. wilson.timothy@gene.com marklackner01@gmail.com., Udyavar AR; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California., Chang CW; Department of Biostatistics, Genentech, Inc., South San Francisco, California., Spoerke JM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Aimi J; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Savage HM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Daemen A; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California., O'Shaughnessy JA; US Oncology, Dallas, Texas.; Baylor University Medical Center, Dallas, Texas.; Texas Oncology, Dallas, Texas., Bourgon R; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California., Lackner MR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. wilson.timothy@gene.com marklackner01@gmail.com.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2019 Jan; Vol. 17 (1), pp. 97-108. Date of Electronic Publication: 2018 Aug 31.